Vor Biopharma director reports sales; 1,166,909 shares remain
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.
Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 200 | $30.075 | $6K |
| Sale | Common Stock | 11,616 | $30.0535 | $349K |
| Sale | Common Stock | 24,689 | $30.2207 | $746K |
| Sale | Common Stock | 1,028 | $31.00 | $32K |
Footnotes (3)
- F1. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
- F3. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Vor Biopharma (VOR) report?
What is the reporting person’s relationship to Vor Biopharma?
Does the filing include a beneficial ownership disclaimer?
Was the Form 4 filed by more than one reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.